Article successfully added.

CyFlow™ CD178 PE

CyFlow™ CD178 PE
Alternative Name: APO-1L, APT1LG, CD95-L, CD95L, Fas-L , FAS-Ligand, TNFSF6 ligand
Antibody: Yes
Antigen: CD178
Application: Flow cytometry
Clonality: monoclonal
Clone: NOK-1
Emission Maximum: 576 nm
Excitation Maximum: 496 nm, 565 nm
Field of Interest: Apoptosis, Immunophenotyping
Format/Fluorochrome: PE
Isotype: IgG1
Laser: Blue , Green, Yellow
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: BZ157747

For Research Use Only

$255.00 USD*

Price excludes any applicable taxes plus shipping costs

Description Documentation TDS & SDS
Description
Quantity 100 tests Volume 1.0 mL Immunogen L5178Y mouse T lymphoma cells expressing... more
Close menu
CyFlow™ CD178 PE
Quantity100 tests
Volume1.0 mL
ImmunogenL5178Y mouse T lymphoma cells expressing recombinant human CD178
Background InformationCD178 (Fas-L; Fas ligand or CD95L), a member of TNF family transmembrane glycoproteins, is responsible for induction of apoptosis in cells containing its receptor Fas/CD95. The CD178-mediated apoptosis pathway has been implicated in peripheral tolerance, tissue pathology, and maintenance of the immune privileged sites. Defects in this interaction may be related to some cases of systemic lupus erythematosus (SLE). CD178 was also described as a co-stimulatory receptor for T-cell activation in mice in vivo.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 10·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H: Metalloproteinase‑mediated release of human Fas ligand. J Exp Med. 1995 Dec 1; 182(6):1777‑83. < PMID: 7500022 > | Ghadimi MP, Sanzenbacher R, Thiede B, Wenzel J, Jing Q, Plomann M, Borkhardt A, Kabelitz D, Janssen O: Identification of interaction partners of the cytosolic polyproline region of CD95 ligand (CD178). FEBS Lett. 2002 May 22; 519(1‑3):50‑8. < PMID: 12023017 > | Chopin D, Barei-Moniri R, Maillé P, Le Frére-Belda MA, Muscatelli-Groux B, Merendino N, Lecerf L, Stoppacciaro A, Velotti F: Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am J Pathol. 2003 Apr; 162(4):1139‑49. < PMID: 12651606 > | Jodo S, Pidiyar VJ, Xiao S, Furusaki A, Sharma R, Koike T, Ju ST: Fas ligand (CD178) cytoplasmic tail is a positive regulator of Fas ligand‑mediated cytotoxicity. J Immunol. 2005 Apr 15; 174(8):4470‑4. < PMID: 15814666 > | Ji J, Chen JJ, Braciale VL, Cloyd MW: Apoptosis induced in HIV‑1‑exposed, resting CD4+ T cells subsequent to signaling through homing receptors is Fas/Fas ligand‑mediated. J Leukoc Biol. 2007 Jan; 81(1):297‑305. < PMID: 17056762 >

TDS & SDS
Close menu

Technical Data Sheet

Safety Data Sheet